Samumed's lorecivivint (SM04690) has entered Phase 3 trials for knee osteoarthritis. Learn what the evidence shows, who may benefit, and how regenerative approaches compare.
Lorecivivint — also known by its development code SM04690 — is an investigational intra-articular drug designed to slow or partially reverse the cartilage deterioration that drives knee osteoarthritis. It works by inhibiting a cellular signalling pathway called Wnt, which, when overactive, accelerates the breakdown of joint tissue. Following encouraging results in a Phase 2 trial, the biotech company Samumed (now operating as Biosplice Therapeutics) advanced it into a Phase 3 clinical programme. This is a meaningful step: Phase 3 is the large-scale human trial stage required before regulators consider approving a treatment.
Knee osteoarthritis is not simply a wear-and-tear problem — though that is how it is often described. At a biological level, it involves a sustained breakdown of articular cartilage, subchondral bone remodelling, low-grade synovial inflammation, and the gradual loss of the joint's load-bearing architecture. Cartilage has no blood supply of its own, which is why it heals poorly and why effective treatment is so difficult to achieve.
The Wnt signalling pathway is a cascade of molecular signals that governs how cells grow, differentiate, and respond to damage. In healthy joints, Wnt activity is tightly regulated. In osteoarthritic joints, dysregulated Wnt signalling contributes to chondrocyte dysfunction — meaning the cells responsible for maintaining cartilage begin to behave in ways that accelerate degradation rather than repair.
The Phase 2 trial — a randomised, placebo-controlled study — enrolled several hundred patients with moderate to severe knee osteoarthritis. The results were genuinely interesting: at specific doses (particularly the 0.07 mg single-injection group), patients showed statistically significant improvement in pain scores and patient-reported function at 52 weeks compared to placebo. Some imaging data also suggested preserved joint space — a proxy measure for cartilage health — in treated knees relative to untreated controls.
The Phase 3 programme is designed to test lorecivivint in a much larger patient population across multiple sites, with the statistical power to detect meaningful differences in outcomes such as pain reduction, physical function, and radiographic joint preservation. If results hold, this data would form the basis of a regulatory submission — likely to the FDA and potentially EMA.
Lorecivivint and MSC-based therapy are both investigational approaches targeting similar biological problems — but they work differently, and the comparison is worth understanding rather than assuming one is superior.
This section matters — and responsible patient education requires stating limitations as clearly as promising findings.
Candidacy for any regenerative joint therapy — whether investigational pharmaceutical or MSC-based — requires individual clinical assessment. General criteria that tend to favour suitability include moderate rather than end-stage osteoarthritis, patients who have not yet reached the threshold for joint replacement, and individuals whose pain and function impairment meaningfully affects quality of life despite standard care.
For patients considering MSC-based joint therapy at our clinic, the process is structured, clinician-led, and transparent. No protocol is applied without a thorough clinical assessment. The pathway typically unfolds as follows.
The MSCs used in joint therapy at our clinic are derived from ethically donated umbilical cord tissue — specifically Wharton's jelly — collected from consented donors following healthy births. Allogeneic cord-derived MSCs have a number of practical and biological advantages for joint applications: they are available in consistent, characterised batches; they are immunologically well-tolerated without HLA matching in most cases; and they carry a well-established safety profile from over 15 years of clinical MSC research across multiple conditions including graft-versus-host disease, Crohn's disease, and orthopaedic indications.
This is one of the most common — and most important — questions international patients ask. The direct answer: receiving MSC-based joint therapy in Istanbul does not require it to be approved or reimbursed in your home country. You are treated under Turkish medical regulation, not under the approval framework of the UK, US, Australia, or wherever you reside. Those are separate legal questions.
Honest outcome framing is a non-negotiable part of how we discuss this therapy. MSC-based joint therapy is not a guaranteed cure, and it does not reverse structural damage in all patients. What published trials and clinical experience suggest is more nuanced: a meaningful proportion of suitable patients report reductions in pain, improvements in joint function, and better quality of life — often beginning 4–12 weeks post-procedure and continuing to develop over 3–6 months.
Allogeneic MSC therapy has a well-documented safety profile in clinical literature. The most commonly reported adverse events for intra-articular injection are transient: localised pain or swelling at the injection site in the days immediately following the procedure, mild fever in a minority of patients, and temporary stiffness. Serious adverse events — including systemic immune reactions — are rare in published trials but cannot be described as impossible, and every patient is monitored accordingly.
The advancement of lorecivivint into Phase 3 signals something important beyond the drug itself: the scientific and commercial recognition that the joint degeneration space requires disease-modifying solutions, not just symptom management. That is the same rationale driving continued clinical investigation of MSC-based approaches, platelet-rich plasma protocols, and exosome-based therapies in joint medicine.
No. As of 2026, lorecivivint (SM04690) is not approved by any major regulatory authority, including the FDA or EMA. It is available only within the context of the ongoing Phase 3 clinical trial programme. Patients interested in trial participation would need to contact Biosplice Therapeutics or check eligibility via ClinicalTrials.gov. This is separate from MSC-based therapies, which are available under specific clinical frameworks in several countries, including Türkiye.
For knee osteoarthritis specifically, the primary route of administration is intra-articular injection — meaning the cells are delivered directly into the joint space using ultrasound guidance for accuracy. This is an outpatient procedure. Patients typically resume light walking the same day and are advised to avoid strenuous activity for a defined recovery window. The intra-articular route is preferred for localised joint pathology because it delivers cells to the target environment directly, rather than via systemic circulation.
This question deserves a direct, honest answer: no, not reliably, and not in all patients. For patients with advanced structural damage and severe functional limitation, total knee replacement remains the most evidence-backed intervention. Stem cell therapy may represent a meaningful option for patients earlier in the disease course — those seeking to delay surgery, improve day-to-day function, or manage pain more effectively than current medications allow. It is a complementary and potentially bridging approach, not a surgical replacement in all cases. A qualified physician who reviews your imaging and clinical history is the only person positioned to advise you on that specific question.
Published trials and clinical experience suggest that patients who respond tend to notice changes between 4 and 12 weeks, with functional improvements continuing to develop over 3–6 months. Some patients report sustained benefit at 12–18 months. The durability of effect varies between individuals and depends on disease stage, lifestyle factors, and continued physiotherapy. Osteoarthritis is a progressive condition — stem cell therapy does not halt the underlying degenerative process in all cases, and some patients may consider repeat sessions over time if clinically indicated.
This is exactly the right question to ask. Key things to confirm: What is the cell source and are donors screened? Is processing GMP-aligned? What is the physician's assessment process before treatment is recommended? What route of administration is used and why? What follow-up is included? What happens if you have a complication after returning home? A clinic that answers these questions transparently — without pressure, without outcome guarantees, and with documented protocols — is operating at a fundamentally different standard than one that promises results before reviewing your case.
It depends on the clinical picture, and that is not a deflection — it is genuinely the correct answer. Patients who have been told they 'may need' a knee replacement in the coming years are often at a stage where regenerative assessment makes clinical sense. Patients who have been told surgery is urgent or immediately necessary for structural instability or severe deformity are in a different position. Our medical team reviews each case individually, including imaging and surgical history, before offering any recommendation. The free consultation is specifically designed to have this conversation honestly.
Lorecivivint (SM04690) Phase 3 Trial for Knee Osteoarthritis: What Patients Need to Know